Immunova

What Immunova does

Immunova is a clinical-stage, pre-revenue oncology company developing first-in-class nanomedicines designed to attack multiple cancer targets simultaneously. The company operates around a proprietary nanotechnology platform described on its corporate website, with its current clinical focus on advanced melanoma and metastatic non-small cell lung cancer (NSCLC). Its lead candidate PORT-2, a liposomal iNKT agonist, was developed by iOx Therapeutics Limited and has completed Phase 1/2 clinical studies in patients in the United States and United Kingdom, with preliminary anti-tumor activity reported. Immunova is headquartered in New Canaan, Connecticut, operates as Immunova, LLC, and is classified as a private company with 11-50 employees.

The company's business model is contingent on future pharmaceutical drug sales contingent on regulatory approval of candidates in development, with a deal structure for the iOx transaction including upfront cash, 10% equity in Immunova, milestone payments potentially exceeding $100 million, and single-digit royalties on future net sales. Immunova has no disclosed funding rounds, no commercial customers, no distribution infrastructure, and no public management team disclosure, leaving its capitalization and leadership details opaque. Its primary commercial interface is a corporate website (immunova.net), and its stated value proposition centers on addressing the limited treatment options for advanced solid tumors through a multi-target therapeutic approach.

In February 2026, Immunova secured a binding call option from AlphaTON Capital Corp to acquire iOx Therapeutics Limited, the developer of PORT-2, which would represent a significant ownership and pipeline transformation if exercised. The company targets oncology patients with advanced or metastatic cancers who have exhausted standard treatment options. No patents, trademarks, certifications, or compliance credentials were disclosed in the input data, limiting the ability to assess intellectual property defensibility.

Name

Immunova

Legal name

Immunova, LLC

Website

https://immunova.net

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Immunova is a clinical-stage, pre-revenue oncology company developing proprietary multi-target nanomedicines for advanced solid tumors. Its lead candidate PORT-2, a liposomal iNKT agonist acquired via a binding call option on iOx Therapeutics, has completed Phase 1/2 studies in melanoma and NSCLC.

Ownership category

akta.pro rank

Product category

Clinical-Stage Oncology Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

Keywords

• Oncology nanomedicines
• Cancer therapeutics
• Liposomal drug delivery
• INKT agonists
• Clinical stage biotech

Headquarters

HQ city

New Canaan

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Drug Sales: Pre-revenue clinical stage company. Future revenue expected from commercializing oncology drug candidates pending regulatory approval. Deal structure includes milestone payments exceeding $100 million and single-digit royalties on future net sales from iOx Therapeutics acquisition option.

Marketing channels1 record

Core offering

Immunova is a clinical-stage oncology company developing proprietary nanotechnology-based medicines intended to engage multiple cancer targets simultaneously. Its lead candidate, PORT-2, is a liposomal iNKT agonist in Phase 1/2 clinical development for advanced melanoma and metastatic NSCLC, originally in-licensed/acquired from iOx Therapeutics.

Product overview

Immunova is a clinical-stage oncology company developing first-in-class medicines using proprietary nanotechnology to attack multiple cancer targets simultaneously. The company is structured around its core nanotechnology platform and holds a call option to acquire iOx Therapeutics Limited, whose lead candidate PORT-2 (a liposomal iNKT agonist) has completed Phase 1/2 clinical studies in advanced melanoma and metastatic NSCLC. The deal structure includes upfront cash, 10% equity, milestone payments exceeding $100 million, and single-digit royalties on future net sales.

Differentiator

Problem solved

Functional benefit

Products and services

• PORT-2 (liposomal iNKT agonist)

Quantifiable outcome

• Preliminary anti-tumor activity observed in Phase 1/2 studies for advanced melanoma and metastatic NSCLC

Segments1 record

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• AlphaTON Capital CorpcoreStrategic or Co-development Partner · 17 February 2026AlphaTON Capital Corp executed a binding call option agreement granting Immunova, LLC the right to acquire iOx Therapeutics Limited, AlphaTON's wholly owned subsidiary developing liposomal iNKT agonists. Under the deal terms, AlphaTON would receive upfront cash payment, 10% equity in the acquiring entity, milestone payments potentially exceeding $100 million, and single-digit royalties on future net sales. iOx's lead candidate PORT-2 has completed Phase 1/2 study in advanced melanoma and metastatic NSCLC patients conducted in the U.S. and U.K.

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Direct peers

• Nanobiotix: Clinical-stage nanomedicine company developing first-in-class oncology products using proprietary nanotechnology platforms. Direct comparable to Immunova given shared focus on nano-enabled, multi-target oncology therapeutics and similar clinical-stage profile.
• iOx Therapeutics Limited: Developer of liposomal iNKT agonists including PORT-2, and the target of Immunova's pending acquisition option from AlphaTON. Directly comparable by mechanism (iNKT agonism), lead asset (PORT-2), and clinical indications (advanced melanoma, metastatic NSCLC).

Broad incumbents

• Bristol Myers Squibb: Major oncology incumbent with leading immuno-oncology franchises (Opdivo, Yervoy) used in advanced melanoma and NSCLC. Comparable as the dominant immunotherapy competitor whose approved products define the standard of care that Immunova's candidates must beat or combine with.
• Merck & Co. Sells Keytruda, the dominant PD-1 inhibitor approved across melanoma and NSCLC. Relevant as the market-leading immunotherapy incumbent whose commercial reach and clinical development machine shape the competitive environment for PORT-2 and similar IO candidates.
• Moderna: mRNA therapeutics platform company with oncology vaccine and intratumoral IO programs. Comparable as a platform-driven cancer immunotherapy player that competes for partnership attention, talent, and capital in the same IO space as Immunova.

Emerging players

• BioNTech: Clinical-stage and commercial mRNA-based immunotherapy company with a pipeline of individualized and off-the-shelf cancer vaccines. Comparable as a next-generation IO developer targeting similar solid tumor indications with platform-driven approaches.
• Arcus Biosciences: Clinical-stage immuno-oncology company developing small-molecule and antibody-based immunotherapies targeting adenosine, TIGIT, and PD-1 pathways. Comparable as a mid-stage IO specialist pursuing novel mechanisms in solid tumors.
• Werewolf Therapeutics: Clinical-stage oncology company developing conditionally activated immunotherapies designed to improve the therapeutic window in solid tumors. Comparable as a platform-driven IO developer at similar clinical maturity to Immunova.
• Compugen: Clinical-stage immuno-oncology company using computational discovery to identify novel drug targets and develop antibody-based IO therapeutics. Comparable as a smaller-cap IO innovator with a novel target/mechanism approach.
• Codiak BioSciences: Clinical-stage developer of engineered exosome therapeutics for cancer and other diseases. Comparable as a small, platform-driven oncology company using a proprietary delivery vehicle — analogous to Immunova's liposomal/nano delivery approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/immunova

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunova